Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03851471 | Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma | EARLY_PHASE1 | COMPLETED | 10 | — | — | Apr 7, 2019 | Mar 30, 2021 | Apr 9, 2021 | 1 | China |
Overall Survival (OS) is defined as the percentage of people in a group who are alive after the 12-week use of drug.
| Arm | Type | Description |
|---|---|---|
| Jiu-wei-zhen-xiao Granule | EXPERIMENTAL | Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment. |
| Name | Type | Description |
|---|---|---|
| Jiu-wei-zhen-xiao Granule | DRUG | Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment. |
Inclusion Criteria: 1. Age:18\~75 years; 2. Patients must have diagnosis of advanced hepatocellular cancer (HCC) by one of the following: (1) Histopathology; (2) Elevated serum alpha-fetoprotein (AFP) \>400 ng/ml and findings on magnetic resonance imaging (MRI) or computed tomography (CT) scans ch...